Irinotecan/floxuridine liposomal
Alternative Names: CPX-1; Floxuridine/irinotecan; Irinotecan HCl:Floxuridine; Irinotecan:Floxuridine; Liposomal irinotecan/floxuridineLatest Information Update: 11 Aug 2016
At a glance
- Originator Celator Pharmaceuticals
- Class Antineoplastics; Camptothecins; Pyrimidine nucleosides; Small molecules
- Mechanism of Action Antimetabolites; DNA topoisomerase I inhibitors; Thymidylate synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Colorectal cancer
Most Recent Events
- 13 Aug 2015 Phase-II development is ongoing in USA and Canada
- 17 Mar 2015 Celator Pharmaceuticals has patent protection for irinotecan/floxuridine in Japan (Celator Pharmaceuticals 10-K, March 2015)
- 01 Apr 2013 Irinotecan/floxuridine is still in phase II trials for Colorectal cancer (second-line therapy or greater, late-stage disease) in Canada and the US